Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 13/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | FPR3 | P25089 | 6/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8547143 | 1.00 | FPR2 (0.56) | FPR2SMN1; SMN2ALDH1A1PKMPOLB | |
| SCHEMBL17922785 | 0.89 | FPR2 (0.49) | FPR2SMN1; SMN2ALDH1A1PKMPOLB | |
| SCHEMBL855772 | 0.84 | FPR2 (0.49) | FPR2SMN1; SMN2ALDH1A1PKMPOLB | |
| SCHEMBL16377663 | 0.84 | FPR2 (0.49) | FPR2SMN1; SMN2ALDH1A1PKMPOLB | |
| SCHEMBL2685419 | 0.80 | PPM1B (0.47) | FPR2SMN1; SMN2ALDH1A1PKMPOLB | |
| SCHEMBL2682902 | 0.80 | PPM1B (0.47) | FPR2SMN1; SMN2ALDH1A1PKMPOLB | |
| SCHEMBL10224384 | 0.80 | PPM1B (0.47) | FPR2SMN1; SMN2ALDH1A1PKMPOLB | |
| SCHEMBL2683926 | 0.80 | PPM1B (0.47) | FPR2SMN1; SMN2ALDH1A1PKMPOLB | |
| SCHEMBL856243 | 0.78 | FPR2 (0.57) | FPR2SMN1; SMN2ALDH1A1PKMFPR3 | |
| SCHEMBL727476 | 0.78 | FPR2 (0.77) | FPR2SMN1; SMN2ALDH1A1PKMFPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676761-B2 | Difluoroethyl-oxazole substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2017-06-13 | — | — | US | disclosed |
| EP-3022188-B1 | PIPERAZINE SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-06-07 | — | — | EP | disclosed |
| EP-3013817-B1 | DIFLUOROETHYL-OXAZOLE SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-9533964-B2 | Piperazine substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-03 | — | — | US | disclosed |
| US-20160289221-A1 | Difluoroethyl-oxazole sustituted bridged spiro[2.4]heptane derivatives as alx receptor agonists | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-10-06 | — | — | US | disclosed |
| EP-2850060-B1 | FLUORINATED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-07-13 | — | — | EP | disclosed |
| EP-2850058-B1 | 1-(P-TOLYL)CYCLOPROPYL SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-20160152584-A1 | PIPERAZINE SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-06-02 | — | — | US | disclosed |
| EP-3022188-A1 | PIPERAZINE SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd (CH) | 2016-05-25 | — | — | EP | disclosed |
| EP-3013817-A1 | DIFLUOROETHYL-OXAZOLE SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2016-05-04 | — | — | EP | disclosed |
| WO-2013171694-A1 | FLUORINATED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-21 | — | — | WO | disclosed |
| WO-2013171687-A1 | 1-(P-TOLYL)CYCLOPROPYL SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-21 | — | — | WO | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2640699-A2 | BRIDGED SPIRO[2.4]HEPTANE ESTER DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-20130231319-A1 | Bridged Spiro[2.4]heptane Ester Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-05 | — | — | US | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012066488-A2 | BRIDGED SPIRO[2.4]HEPTANE ESTER DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | FPR2 2/4885SMN1; SMN2 3806/4885ALDH1A1 1293/4885 |
| US-20160289221-A1 | Difluoroethyl-oxazole sustituted bridged spiro[2.4]heptane derivatives as alx receptor agonists | GPR39, P2RX1, P2RX4 | FPR2 453/4885SMN1; SMN2 2475/4885ALDH1A1 314/4885 |
| US-20130231319-A1 | Bridged Spiro[2.4]heptane Ester Derivatives | ADH1A, ADH1C, NAPA | FPR2 1944/4885SMN1; SMN2 1193/4885ALDH1A1 609/4885 |
| US-20160152584-A1 | PIPERAZINE SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | GPR52, P2RX2, HCAR2 | FPR2 236/4885SMN1; SMN2 3511/4885ALDH1A1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.